About Brightpath Biotherapeutics

Sponsor retains sole responsibility for content.

BrightPath Biotherapeutics, formerly GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies, s...

BrightPath Biotherapeutics, formerly GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies, so we would like to take an opportunity to introduce our out-licensing candidates. We also search for in-licensing and/or research collaboration opportunities in I/O field.

Contact Brightpath Biotherapeutics

Phone Number
+81-3-5840-7697

More About Brightpath Biotherapeutics

Therapeutic Areas
  • Oncology
Technologies
  • Peptides
  • Regenerative medicine
  • Vaccines
Company Type
  • Pharmaceutical
State of Ownership
  • Public
Sponsorship Group
  • Networker